Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of RAPT is 58 and suggests 0% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decrea
Buy
Sell